28086772|t|Scutellaria barbata D. Don extract inhibits the tumor growth through down-regulating of Treg cells and manipulating Th1 / Th17 immune response in hepatoma H22 -bearing mice
28086772|a|Previous studies showed Scutellaria barbata D. Don extract (SBE) is a potent inhibitor in hepatoma and could improve immune function of hepatoma H22 -bearing mice. However, the immunomodulatory function of SBE on the tumor growth of hepatoma remains unclear. This study aimed to investigate the anti-tumor effects of SBE on hepatoma H22 -bearing mice and explore the underlying immunomodulatory function. The hepatoma H22 -bearing mice were treated by SBE for 30 days. The effect of SBE on the proliferation of HepG2 cells in vitro, the growth of transplanted tumor, the cytotoxicity of natural killer (NK) cells in spleen, the amount of CD4(+)CD25(+)Foxp3(+) Treg cells and Th17 cells in tumor tissue, and the levels of IL-10, TGF-β, IL-17A, IL-2, and IFN-γ in serum of the hepatoma H22 -bearing mice was observered. IL-17A was injected to the SBE treated mice from day 9 post H22 inoculation to examine its effect on tumor growth. SBE treatment inhibited the proliferation of HepG2 cells in vitro with a dose-dependent manner and significantly suppressed the tumor growth of hepatoma H22 -bearing mice. Meanwhile, it increased NK cells' cytotoxicity in spleen, down-regulated the amount of CD4(+)CD25(+)Foxp3(+) Treg cells and Th17 cells in tumor tissue, and decreased IL-10, TGF-β, and IL-17A levels (P < 0.01) whereas increased IL-2 and IFN-γ levels (P < 0.01) in the serum of hepatoma H22 -bearing mice. Moreover, administration of recombinant mouse IL-17A reversed the anti-tumor effects of SBE. SBE could inhibit the proliferation of HepG2 cells in vitro. Meanwhile, SBE also could inhibit the growth of H22 implanted tumor in hepatoma H22 -bearing mice, and this function might be associated with immunomodulatory activity through down-regulating of Treg cells and manipulating Th1 / Th17 immune response.
28086772	0	34	Scutellaria barbata D. Don extract	T103	UMLS:C1999758
28086772	69	84	down-regulating	T038	UMLS:C0013081
28086772	88	98	Treg cells	T017	UMLS:C0039198
28086772	103	115	manipulating	T038	UMLS:C2584326
28086772	116	119	Th1	T038	UMLS:C1155080
28086772	122	142	Th17 immune response	T038	UMLS:C3156592
28086772	168	172	mice	T204	UMLS:C0025929
28086772	197	231	Scutellaria barbata D. Don extract	T103	UMLS:C1999758
28086772	233	236	SBE	T103	UMLS:C1999758
28086772	250	259	inhibitor	T103	UMLS:C0018282
28086772	263	271	hepatoma	T038	UMLS:C0023903
28086772	290	305	immune function	T038	UMLS:C1817756
28086772	331	335	mice	T204	UMLS:C0025929
28086772	350	375	immunomodulatory function	T038	UMLS:C1148560
28086772	379	382	SBE	T103	UMLS:C1999758
28086772	406	414	hepatoma	T038	UMLS:C0023903
28086772	437	442	study	T062	UMLS:C2603343
28086772	490	493	SBE	T103	UMLS:C1999758
28086772	519	523	mice	T204	UMLS:C0025929
28086772	551	576	immunomodulatory function	T038	UMLS:C1148560
28086772	604	608	mice	T204	UMLS:C0025929
28086772	625	628	SBE	T103	UMLS:C1999758
28086772	656	659	SBE	T103	UMLS:C1999758
28086772	667	680	proliferation	T038	UMLS:C0596290
28086772	684	695	HepG2 cells	T017	UMLS:C2717940
28086772	744	785	cytotoxicity of natural killer (NK) cells	T038	UMLS:C1159807
28086772	789	795	spleen	T017	UMLS:C0037993
28086772	811	843	CD4(+)CD25(+)Foxp3(+) Treg cells	T103	UMLS:C3830403
28086772	848	858	Th17 cells	T017	UMLS:C2936411
28086772	862	874	tumor tissue	T017	UMLS:C0475358
28086772	894	899	IL-10	T103	UMLS:C3179724
28086772	901	906	TGF-β	T103	UMLS:C0076930
28086772	908	914	IL-17A	T103	UMLS:C1705947
28086772	916	920	IL-2	T103	UMLS:C0021756
28086772	926	931	IFN-γ	T103	UMLS:C0211279
28086772	935	940	serum	T031	UMLS:C0229671
28086772	970	974	mice	T204	UMLS:C0025929
28086772	991	997	IL-17A	T103	UMLS:C1705947
28086772	1018	1021	SBE	T103	UMLS:C1999758
28086772	1030	1034	mice	T204	UMLS:C0025929
28086772	1055	1066	inoculation	T058	UMLS:C2987620
28086772	1106	1109	SBE	T103	UMLS:C1999758
28086772	1134	1147	proliferation	T038	UMLS:C0596290
28086772	1151	1162	HepG2 cells	T017	UMLS:C2717940
28086772	1272	1276	mice	T204	UMLS:C0025929
28086772	1302	1324	NK cells' cytotoxicity	T038	UMLS:C1159807
28086772	1328	1334	spleen	T017	UMLS:C0037993
28086772	1336	1350	down-regulated	T038	UMLS:C0013081
28086772	1365	1397	CD4(+)CD25(+)Foxp3(+) Treg cells	T103	UMLS:C3830403
28086772	1402	1412	Th17 cells	T017	UMLS:C2936411
28086772	1416	1428	tumor tissue	T017	UMLS:C0475358
28086772	1444	1449	IL-10	T103	UMLS:C3179724
28086772	1451	1456	TGF-β	T103	UMLS:C0076930
28086772	1462	1468	IL-17A	T103	UMLS:C1705947
28086772	1505	1509	IL-2	T103	UMLS:C0021756
28086772	1514	1519	IFN-γ	T103	UMLS:C0211279
28086772	1545	1550	serum	T031	UMLS:C0229671
28086772	1576	1580	mice	T204	UMLS:C0025929
28086772	1610	1627	recombinant mouse	T204	UMLS:C0025929
28086772	1628	1634	IL-17A	T103	UMLS:C1705947
28086772	1670	1673	SBE	T103	UMLS:C1999758
28086772	1675	1678	SBE	T103	UMLS:C1999758
28086772	1697	1710	proliferation	T038	UMLS:C0596290
28086772	1714	1725	HepG2 cells	T017	UMLS:C2717940
28086772	1747	1750	SBE	T103	UMLS:C1999758
28086772	1774	1780	growth	T038	UMLS:C0007595
28086772	1788	1803	implanted tumor	T038	UMLS:C0027651
28086772	1829	1833	mice	T204	UMLS:C0025929
28086772	1878	1903	immunomodulatory activity	T038	UMLS:C1148560
28086772	1912	1927	down-regulating	T038	UMLS:C0013081
28086772	1931	1941	Treg cells	T017	UMLS:C0039198
28086772	1946	1958	manipulating	T038	UMLS:C2584326
28086772	1959	1962	Th1	T038	UMLS:C1155080
28086772	1965	1985	Th17 immune response	T038	UMLS:C3156592